SEC Form 4 · accession 0001179110-18-013009
MADRIGAL PHARMACEUTICALS, INC. · MDGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred B Craves
Director · 10% Owner
Period of report
Nov 19, 2018
Accepted (ET)
Nov 19, 2018 · 6:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157601
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 19, 2018 | P | 100 | $123.17 | A | 296,167 | D | |
| Common StockF1 | Nov 19, 2018 | P | 1,000 | $124.57 | A | 297,167 | D | |
| Common Stock | Nov 19, 2018 | P | 900 | $125.00 | A | 298,067 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.00 to $124.82, inclusive. Thereporting person undertakes to provide to Madrigal Pharmaceuticals, Inc., any security holder of Madrigal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.